Cosentyx (secukinumab) is a biologic medication used to treat various autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The recommended dosage of Cosentyx depends on the specific condition being treated and the patient's weight. According to the drug label provided by Novartis, the recommended initial dose for adult patients with psoriasis or psoriatic arthritis is 300 mg, given as two subcutaneous injections of 150 mg each, at weeks 0, 1, 2, 3, and 4. After the initial five doses, the recommended maintenance dose is 300 mg every four weeks [3]. For patients with ankylosing spondylitis, the recommended initial dose is 150 mg every four weeks for the first three doses, followed by 150 mg every four weeks or 300 mg every four weeks, depending on the patient's response [3].

Adjustments to the dosage of Cosentyx may be necessary based on the patient's response to treatment. If the patient does not show improvement after 12 weeks of treatment, it is recommended to discontinue Cosentyx [2]. Additionally, if a patient experiences an adverse reaction to the medication, the dosage may need to be adjusted or the treatment may need to be discontinued altogether [1].

In conclusion, the recommended dosage of Cosentyx varies depending on the condition being treated and the patient's weight. Adjustments to the dosage may be necessary based on the patient's response to treatment or if adverse reactions occur. It is important to follow the prescribing physician's instructions and to report any concerning symptoms to the healthcare provider [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.healthline.com/health/drugs/cosentyx-dosage
[3] https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf